10x Genomics Collaborates with Cancer Research Institute to Advance Immuno-Oncology Research

10x Genomics Partners with Cancer Research Institute to Transform Immuno-Oncology Research

10x Genomics, Inc., a leader in single-cell and spatial biology, announces a groundbreaking collaboration with the Cancer Research Institute (CRI) that aims to enhance immuno-oncology research through the integration of high-resolution molecular data and artificial intelligence (AI). This multi-phase initiative seeks to generate over 20,000 samples from leading immuno-oncology laboratories, creating one of the most comprehensive datasets in the field. The collaboration begins with a pilot phase involving approximately 3,000 samples, analyzed using 10x's renowned Chromium single-cell and Xenium spatial platforms. These platforms are recognized for their ability to produce large-scale, high-quality datasets that are essential for AI-driven analyses. The pilot datasets will serve as benchmarks for early AI models, pinpointing which cellular and microenvironmental features are most predictive in preclinical settings.

In the subsequent full-scale phase of the project, the collaboration will expand to a broader network of laboratories, significantly increasing the volume of sample generation. CRI plans to utilize 10x's Chromium Flex single-cell assay, designed for ultra high-throughput studies, to profile over 500 million cells during this phase. This integrated dataset aims to uncover mechanisms of immune response and resistance, refine existing immuno-oncology therapies, and identify new treatment opportunities. The collaboration's ultimate goal is to drive the next generation of immunotherapies and vaccine discoveries by mapping the immune landscape of cancer, ultimately informing smarter treatment and prevention strategies for the future.

Leading researchers from prestigious institutions, including John Wherry from the University of Pennsylvania and Ansuman Satpathy from Stanford University, will spearhead this pioneering effort. Their expertise will play a crucial role in analyzing the complex data generated, thereby enabling researchers to identify actionable insights that could improve patient outcomes in immuno-oncology. By focusing on the interplay between cancer and the immune system, this collaboration not only positions 10x Genomics at the forefront of scientific innovation but also reaffirms the growing importance of integrating AI with molecular biology in the quest for more effective cancer treatments.

In related news, 10x Genomics has also formed a strategic alliance with Dana-Farber Cancer Institute to enhance cancer treatment through biomarker identification, focusing on precision oncology. This initiative will analyze tumor samples from hundreds of patients, aiming to correlate biological features with treatment responses and resistance mechanisms across various therapies.

Moreover, the company is set to establish a CLIA-certified laboratory to develop innovative diagnostic tests that will integrate single-cell and spatial tumor analyses into clinical workflows. This initiative aligns with the ongoing efforts of 10x Genomics to revolutionize cancer care through cutting-edge technologies and collaborative research.